Journal of Cancer Research and Clinical Oncology

, Volume 137, Issue 9, pp 1337–1342

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

  • Charles Butts
  • Andrew Maksymiuk
  • Glenwood Goss
  • Denis Soulières
  • Ernie Marshall
  • Yvon Cormier
  • Peter M. Ellis
  • Allan Price
  • Ravinder Sawhney
  • Frank Beier
  • Martin Falk
  • Nevin Murray
Original Paper

DOI: 10.1007/s00432-011-1003-3

Cite this article as:
Butts, C., Maksymiuk, A., Goss, G. et al. J Cancer Res Clin Oncol (2011) 137: 1337. doi:10.1007/s00432-011-1003-3

Abstract

Purpose

To present an updated survival analysis of an open-label, parallel-group, phase IIB trial of BLP25 liposome vaccine (L-BLP25) in patients with stage IIIB or IV non-small-cell lung cancer (NSCLC).

Methods

Patients were randomized to either L-BLP25 plus best supportive care (BSC) or BSC alone. Patients in the L-BLP25 arm received subcutaneous vaccinations of L-BLP25 930 μg weekly for 8 weeks, followed by maintenance vaccinations at 6-week intervals.

Results

Median survival time was 4.2 months longer in patients receiving L-BLP25 plus BSC (n = 88) than in those receiving BSC alone (n = 83; 17.2 months vs. 13.0 months, respectively; hazard ratio [HR] 0.745, 95% confidence interval [CI] 0.533–1.042). The 3-year survival rate was 31% in patients receiving L-BLP25 plus BSC and 17% in those receiving BSC (P = 0.035). In the stratified subset of patients with stage IIIB loco-regional (LR) disease, median survival time was 17.3 months longer in patients receiving L-BLP25 plus BSC (n = 35) than in those receiving BSC (n = 30; 30.6 months vs. 13.3 months, respectively; HR 0.548, 95% CI 0.301–0.999). In this subgroup, 3-year survival was 49% in patients receiving L-BLP25 plus BSC and 27% in those receiving BSC (P = 0.070).

Conclusions

Confirming the initial results, further follow-up continues to show that survival time for patients with stage IIIB/IV NSCLC was longer with L-BLP25 plus BSC compared with BSC alone, with the greatest difference seen in patients with stage IIIB LR disease.

Keywords

Survival Non-small-cell lung cancer Therapeutic cancer vaccine L-BLP25 MUC1 

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Charles Butts
    • 1
  • Andrew Maksymiuk
    • 2
  • Glenwood Goss
    • 3
  • Denis Soulières
    • 4
  • Ernie Marshall
    • 5
  • Yvon Cormier
    • 6
  • Peter M. Ellis
    • 7
  • Allan Price
    • 8
  • Ravinder Sawhney
    • 9
  • Frank Beier
    • 10
  • Martin Falk
    • 10
  • Nevin Murray
    • 11
  1. 1.Cross Cancer InstituteEdmontonCanada
  2. 2.CancerCare ManitobaWinnipegCanada
  3. 3.The Ottawa Hospital Cancer CentreOttawaCanada
  4. 4.Centre Hospitalier de l’Université de MontrealMontrealCanada
  5. 5.Clatterbridge Centre for OncologyBebingtonUK
  6. 6.Universite LavalSainte-FoyCanada
  7. 7.Juravinski Cancer CentreHamiltonCanada
  8. 8.Western General HospitalEdinburghUK
  9. 9.Fraser Valley Cancer CentreSurreyCanada
  10. 10.Merck KGaADarmstadtGermany
  11. 11.Vancouver Cancer CentreVancouverCanada

Personalised recommendations